임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

16건 표시

3상모집 중단 (진행 중)· Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
리드: 사노피 · 협력: 리제네론
상세 →NCT06834347
3상모집 중단 (진행 중)· Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
리드: 사노피 · 협력: 리제네론
상세 →NCT06834360
3상모집 중단 (진행 중)· Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
리드: 리제네론
상세 →NCT06548100
3상모집 중단 (진행 중)· Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
리드: 사노피 · 협력: 리제네론
상세 →NCT06687967
3상모집 중단 (진행 중)· Lichen Simplex Chronicus
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
리드: 사노피 · 협력: 리제네론
상세 →NCT06687980
3상모집 중단 (진행 중)· Neovascular Age-Related Macular Degeneration
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
리드: 리제네론
상세 →NCT06491914
3상모집 중단 (진행 중)· B-Cell Non-Hodgkin Lymphoma (B-NHL)
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
리드: 리제네론
상세 →NCT06230224
3상모집 중단 (진행 중)· Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
리드: 사노피 · 협력: 리제네론
상세 →NCT06208306
3상모집 중단 (진행 중)· Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
리드: 리제네론
상세 →NCT06097364
3상모집 중단 (진행 중)· Melanoma
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
리드: 리제네론
상세 →NCT05608291
3상모집 중단 (진행 중)· Fibrodysplasia Ossificans Progressiva
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
리드: 리제네론
상세 →NCT05394116
3상모집 중단 (진행 중)· Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
리드: 리제네론
상세 →NCT05133531
3상모집 중단 (진행 중)· Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
리드: 리제네론
상세 →NCT05352672
3상모집 중단 (진행 중)· Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
리드: 리제네론
상세 →NCT05070858
3상모집 중단 (진행 중)· Cutaneous Squamous Cell Carcinoma
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
리드: 리제네론
상세 →NCT03969004
3상모집 중단 (진행 중)· Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
리드: 리제네론 · 협력: 사노피
상세 →NCT02612454

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.